Nothing Special   »   [go: up one dir, main page]

Joyce, 2023 - Google Patents

Antibody Sequencing and Immune Responses

Joyce, 2023

Document ID
15518075724044663601
Author
Joyce C
Publication year

External Links

Snippet

Millions of people continue to die from HIV despite wide-spread use of antiretroviral drugs, signaling the need to develop an effective vaccine. It is well established that neutralizing antibodies play a large role in anti-viral protection and will need to be induced by …
Continue reading at search.proquest.com (other versions)

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses, e.g. hepatitis E virus
    • C07K16/1036—Retroviridae, e.g. leukemia viruses
    • C07K16/1045—Lentiviridae, e.g. HIV, FIV, SIV
    • C07K16/1063—Lentiviridae, e.g. HIV, FIV, SIV env, e.g. gp41, gp110/120, gp160, V3, PND, CD4 binding site
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse Transcribing RNA Viruses
    • C12N2740/00011—Reverse Transcribing RNA Viruses
    • C12N2740/10011—Retroviridae

Similar Documents

Publication Publication Date Title
Jardine et al. Minimally mutated HIV-1 broadly neutralizing antibodies to guide reductionist vaccine design
Sok et al. The effects of somatic hypermutation on neutralization and binding in the PGT121 family of broadly neutralizing HIV antibodies
Zhou et al. Multidonor analysis reveals structural elements, genetic determinants, and maturation pathway for HIV-1 neutralization by VRC01-class antibodies
Wu et al. Maturation and diversity of the VRC01-antibody lineage over 15 years of chronic HIV-1 infection
McCarthy et al. Memory B cells that cross-react with group 1 and group 2 influenza A viruses are abundant in adult human repertoires
Cale et al. Virus-like particles identify an HIV V1V2 apex-binding neutralizing antibody that lacks a protruding loop
Crowe Principles of broad and potent antiviral human antibodies: insights for vaccine design
Doyle-Cooper et al. Immune tolerance negatively regulates B cells in knock-in mice expressing broadly neutralizing HIV antibody 4E10
Kumar et al. An HIV-1 broadly neutralizing antibody from a clade C-infected pediatric elite neutralizer potently neutralizes the contemporaneous and autologous evolving viruses
Moore et al. Ontogeny‐based immunogens for the induction of V2‐directed HIV broadly neutralizing antibodies
US10273291B2 (en) Focused evolution of HIV-1 neutralizing antibodies revealed by crystal structures and deep sequencing
Prabakaran et al. Origin, diversity, and maturation of human antiviral antibodies analyzed by high-throughput sequencing
US20200199204A1 (en) Broadly Neutralizing Monoclonal Antibodies Against HIV-1 V1V2 Env Region
Navis et al. HIV-1 receptor binding site-directed antibodies using a VH1-2 gene segment orthologue are activated by Env trimer immunization
Delhalle et al. Phages and HIV-1: From display to interplay
Shah et al. Insights from analysis of human antigen-specific memory B cell repertoires
Kuwata et al. Conformational epitope consisting of the V3 and V4 loops as a target for potent and broad neutralization of simian immunodeficiency viruses
Kumar et al. A VH1-69 antibody lineage from an infected Chinese donor potently neutralizes HIV-1 by targeting the V3 glycan supersite
Mokhtary et al. Recent progress in the discovery and development of monoclonal antibodies against viral infections
Mendoza et al. COVID-19 antibody development fueled by HIV-1 broadly neutralizing antibody research
Joyce Antibody Sequencing and Immune Responses
Joyce et al. Antigen pressure from two founder viruses induces multiple insertions at a single antibody position to generate broadly neutralizing HIV antibodies
Kreer et al. Probabilities of HIV-1 bNAb development in healthy and chronically infected individuals
Wang et al. A key F27I substitution within HCDR1 facilitates the rapid maturation of P2C-1F11-like neutralizing antibodies in a SARS-CoV-2-infected donor
Bullen et al. Deep mining of early antibody response in COVID-19 patients yields potent neutralisers and reveals high level of convergence